Biotech: Page 3


  • Pigs
    Image attribution tooltip
    Scott Olson/Staff via Getty Images
    Image attribution tooltip

    With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care

    Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.

    By Kelly Bilodeau • April 1, 2024
  • Rivus Pharmaceuticals drugs
    Image attribution tooltip
    Permission granted by Rivus Pharmaceuticals
    Image attribution tooltip

    To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach

    Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.

    By March 29, 2024
  • cancer healthcare Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • Claudia Ulbrich, CEO, Cardior Pharmaceuticals
    Image attribution tooltip
    Permission granted by Cardior
    Image attribution tooltip

    ‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field

    Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.

    By March 28, 2024
  • A person in hiking gear stands for a photograph with mountains in the background.
    Image attribution tooltip
    Permission granted by Art Krieg
    Image attribution tooltip

    Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup

    With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told BioPharma Dive.

    By Ben Fidler • March 28, 2024
  • Bernice Bennett, genealogist
    Image attribution tooltip
    Permission granted by Alnylam
    Image attribution tooltip

    Alnylam turns to genealogy to find rare disease patients through family trees

    A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.

    By March 26, 2024
  • A headshot of Armon Sharei, CEO of Portal Bio.
    Image attribution tooltip
    Permission granted by Portal Bio
    Image attribution tooltip
    Q&A

    SQZ, Portal founder Armon Sharei on starting over in biotech

    After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.

    By Gwendolyn Wu • March 26, 2024
  • Weight loss GLP-1
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Who’s getting left behind in the weight loss bonanza?

    As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.

    By Kelly Bilodeau • March 25, 2024
  • Bogdan Budnik, principal scientist, Wyss Institute at Harvard University
    Image attribution tooltip
    Permission granted by Wyss Institute
    Image attribution tooltip
    Q&A

    An ocean of answers in a single cell — how proteomics can lead to better drugs

    New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.

    By March 21, 2024
  • Colorful DNA double helix.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Orchard sets out to sell world’s priciest gene therapy

    Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market. 

    By Kristin Jensen • March 20, 2024
  • bottle of Rezdiffra
    Image attribution tooltip
    Courtesy of Madrigal
    Image attribution tooltip

    With historic MASH approval, Madrigal preps for launch and a public offering

    After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.

    By March 20, 2024
  • shingles vaccine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

    Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

    By Alexandra Pecci • March 19, 2024
  • Business vision to see opportunity, investor fortune or profit growth, career achievement concept, smart businessman manager using telescope to see future standing on top of rising arrow market graph.
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help

    A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.

    By March 19, 2024
  • brain pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After Amylyx drug failure, what’s next for ALS?

    The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

    By March 15, 2024
  • U.S. President Joe Biden
    Image attribution tooltip
    Alex Wong/Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

    A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

    By March 14, 2024
  • stock numbers below a NYSE sign
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    These biotech hotspots are ripe for IPOs

    Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.

    By March 13, 2024
  • liquid biopsy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

    As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

    By Alexandra Pecci • March 12, 2024
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

    Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

    By March 12, 2024
  • lightbulb brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D

    The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.

    By Kelly Bilodeau • March 11, 2024
  • two street signs pointing in opposite directions
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter

    With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.

    By March 11, 2024
  • Dr. Marc Conant, chief medical officer, American Gene Technologies
    Image attribution tooltip
    Permission granted by Natalie Ferguson/American Gene Technologies
    Image attribution tooltip
    Profile

    HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

    From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

    By March 5, 2024
  • The staff of CG Oncology rings the opening bell at Nasdaq as confetti falls.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc.
    Image attribution tooltip

    Biotech IPOs heated up to start 2024. Will the surge last?

    Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead. 

    By Gwendolyn Wu , Ben Fidler • March 5, 2024
  • Sanofi HQ
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Did the FTC get it wrong when it blocked the Sanofi-Maze deal?

    In its zeal to stamp out anticompetitive practices and lower drug prices, a consultant said the FTC might have overlooked the unique considerations in rare disease drug development.

    By Alexandra Pecci • March 4, 2024
  • lots of colorful pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Black Diamond looks to outwit cancer mutations

    Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

    By Kelly Bilodeau • March 4, 2024
  • Neuron ALS
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    By Feb. 29, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a top scientist and Moderna co-founder change the CRO game?

    From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

    By Feb. 28, 2024